Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...

CMS has launched the third RMADA contract vehicle with a $3.5 billion ceiling over five years Seventeen companies secured spots after a competition that drew 34 offers The contract supports research ...

Expanding on IVBM insights, Robert Kratzke, MD, discusses biomarkers, NGS panels, and treatment options for early-stage NSCLC without actionable alterations.

Dune 3 – officially titled Dune: Part Three – is only months away as we'll be heading back to Arrakis this December. We're waiting patiently for a new trailer, and it seems we'll be getting one soon ...